Advertisement
| braf targeted therapy drugs: Cutaneous Melanoma , |
| braf targeted therapy drugs: Dermatologic Principles and Practice in Oncology Mario E. Lacouture, 2013-11-26 The first book focusing specifically on frequent and frequently disabling side effects involving the skin, hair and nails in cancer patients According to the World Health Organization, there are approximately thirty million people living with a diagnosis of cancer – the majority of whom will receive surgery, systemic therapy, and/or radiation, and who will suffer from dermatologic adverse events. Dermatologists and oncologists are only beginning to grapple with these events, which pose serious quality-of-life issues with so many patients, and will become more prevalent as survival rates improve, thanks in part to new cancer treatments and drug regimens. Concentrating on a topic that has only been briefly touched upon by other texts, this book offers a focused perspective on the clinical presentation, underlying pathophysiologic mechanisms, and management of skin, hair, and nail conditions for oncologists, dermatologists, and allied practitioners. Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients: • Covers in detail the dermatologic adverse events of oncologic therapies, clinical presentations, and treatment recommendations • Enables dermatologists and other practitioners to significantly improve the care of patients with cancer • Addresses the dermatologic adverse events of cancer therapies used globally, of which a large number are found in developing countries • Emphasizes prophylactic measures – based on treatments used and type of cancer – to prevent the appearance of adverse events • Provides built-in discussions on patient education for practical counseling during therapies • Offers rapid-reference sections on topical dermatology drugs The first book to present dermatologic conditions in cancer patients and survivors in a uniform and in-depth manner, Dermatologic Principles and Practice in Oncology is ideal for oncologists, oncology nurses, and dermatologists who wish to take better care of those with adverse skin, hair, and nail conditions. |
| braf targeted therapy drugs: Central Nervous System Metastases Manmeet Ahluwalia, Philippe Metellus, Riccardo Soffietti, 2019-11-05 This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and immunotherapy. These combination strategies represent a new therapeutic model in brain metastatic patients in which each medical practitioner (neurosurgeon, neurologist, medical oncologist, radiation oncologist) plays a pivotal role in defining the optimal treatment in a multidisciplinary approach. Written by recognized experts in the field, this book is a valuable tool for neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, radiation oncologists, cognitive therapists, basic scientists and students working in the area of brain tumors. |
| braf targeted therapy drugs: IASLC Thoracic Oncology E-Book Harvey Pass, David Ball, Giorgio Scagliotti, 2017-04-21 Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today's best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies. - Offers practical, relevant coverage of basic science, epidemiology, pulmonology, medical and radiation oncology, surgery, pathology, palliative care, nursing, and advocacy. - Provides authoritative guidance from the IASLC – the only global organization dedicated to the study of lung cancer. - Includes new content on molecular testing, immunotherapy, early detection, staging and the IASLC staging system, surgical resection for stage I and stage II lung cancer, and stem cells in lung cancer. - Features a new full-color design throughout, as well as updated diagnostic algorithms. - Expert ConsultTM eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, Q&As, and references from the book on a variety of devices. |
| braf targeted therapy drugs: Introduction to Basics of Pharmacology and Toxicology Abialbon Paul, Nishanthi Anandabaskar, Jayanthi Mathaiyan, Gerard Marshall Raj, 2021-03-13 This book explains the pharmacological relationships between the various systems in the human body. It offers a comprehensive overview of the pharmacology concerning the autonomic, central, and peripheral nervous systems. Presenting up-to-date information on chemical mediators and their significance, it highlights the therapeutic aspects of several diseases affecting the cardiovascular, renal, respiratory, gastrointestinal, endocrinal, and hematopoietic systems. The book also includes drug therapy for microbial and neoplastic diseases. It also comprises sections on immunopharmacology, dermatological, and ocular pharmacology providing valuable insights into these emerging and recent topics. Covering the diverse groups of drugs acting on different systems, the book reviews their actions, clinical uses, adverse effects, interactions, and subcellular mechanisms of action. It is divided into 11 parts, subdivided into several chapters that evaluate the basic pharmacological principles that govern the different types of body systems. This book is intended for academicians, researchers, and clinicians in industry and academic institutions in pharmaceutical, pharmacological sciences, pharmacy, medical sciences, physiology, neurosciences, biochemistry, molecular biology and other allied health sciences. |
| braf targeted therapy drugs: Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy , 2018-11-21 Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. - Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research - Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms - Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment |
| braf targeted therapy drugs: Sunlight, Vitamin D and Skin Cancer Jörg Reichrath, 2020-09-11 The third edition is a comprehensive and updated overview of positive and negative effects of UV-exposure, with a focus on Vitamin D and skin cancer. Researchers, oncologists,and students will be provided with the most significant and timely information related to topics such as the epidemiology of skin cancer, the immune system and skin cancer, ultraviolet damage, DNA repair and Vitamin D in Nonmelanoma skin cancer and malignant melanoma. There have been a number of new, scientific findings in this fast moving field that necessitated a thoroughly updated and revised edition including new Vitamin D metabolites and skin cancer, new findings on the beneficial effects of UV and solar UV and skin cancer, adverse effects of sun protection and sunscreens, sun exposure and mortality, and more. The book will summarize essential, up-to-date information for every clinician or scientist interested in how to balance the positive and negative effects of UV‐exposure to minimize the risks of developing vitamin D deficiency and skin cancer. |
| braf targeted therapy drugs: Lung Cancer: A Practical Approach to Evidence-Based Clinical Evaluation and Management Lynn T. Tanoue, Frank C Detterbeck, 2018-05-30 Get a quick, expert overview of the many key facets of lung cancer evaluation and management with this concise, practical resource by Drs. Lynn T. Tanoue and Frank Detterbeck. This easy-to-read reference presents a summary of today's best evidence-based approaches to diagnosis and management in this critical area. - Covers diagnosis and evaluation, treatment considerations, and comprehensive care options for patients with lung cancer. - Provides insight on evidence for today's best practices, as well as future directions in the field. - Consolidates today's evidence-based information on the clinical aspects of lung cancer into one convenient resource. |
| braf targeted therapy drugs: Targeted Therapies in Oncology, Second Edition Giuseppe Giaccone, Jean-Charles Soria, 2013-10-21 Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments. These therapies notably include: Targeted agents of immune checkpoints Signal-transduction inhibitors Antiangiogenic agents Vascular-disrupting agents Apoptosis modulators Stem cell inhibitors Tumor profiling for drug development The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world. |
| braf targeted therapy drugs: Weedon's Skin Pathology E-Book James W. Patterson, 2019-11-19 Encyclopedic and authoritative, Weedon’s Skin Pathology has earned outstanding reviews and accolades from practicing and trainee dermatopathologists, general pathologists, and dermatologists worldwide. The 5th Edition continues the tradition of excellence, helping you accurately and efficiently sign out challenging skin cases in everyday practice, while also keeping you up to date with recent advances in the field. This single-authored text provides comprehensive coverage of the full spectrum of dermatopathological entities, both inflammatory and neoplastic, highlighted by more than 1,200 large-sized, high-quality illustrations. Helps you arrive at the most accurate diagnoses possible by demonstrating what is seen through the microscope and identifying the characteristic features of the lesion – for established disorders, unusual and rare disease entities, and incompletely defined entities. Includes updated and expanded information on molecular diagnostics, including FISH (fluorescence in situ hybridization) techniques, plus new developments in molecular biology and molecular techniques, targeted-personalized medicine, and immunohistochemistry. Brings you fully up to date with carefully reviewed and streamlined introductory and basic science information and information on new entities since the previous edition. Presents even more key information in quick-reference formats such as tables and boxes that organize diseases into groups, synthesize diagnostic criteria, and list differential diagnoses. Identifies both important articles and more rare and unusual reports with remarkably authoritative, comprehensive, current, and relevant reference lists (over 35,000) for each entity. Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices. |
| braf targeted therapy drugs: Molecular Basis of Thyroid Cancer NADIR R. FARID, 2006-02-03 - This series is indexed in index Medicus - The turn around time for this series is fast, making the research as accurate as a journal |
| braf targeted therapy drugs: Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners Marianne Davies, Beth Eaby-Sandy, 2019-07-16 This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment. |
| braf targeted therapy drugs: Cutaneous Melanoma Giuseppe Argenziano, Aimilios Lallas, Caterina Longo, Elvira Moscarella, Athanassios Kyrgidis, Gerardo Ferrara, 2017-08-15 Cutaneous Melanoma: A Pocket Guide for Diagnosis and Management serves as an easy-to-consult, short, and schematic reference providing guidelines for diagnosing and managing melanoma in the context of various clinical scenarios. In the daily routine of a busy clinician, there is a need for schematic reference tools that allow quick consultation for immediate decisions. Melanoma is a deadly disease that should be promptly managed following precise and evidence-based guidelines. The guide contains many schematics and figures, vastly outnumbering the pages dedicated to text. This guide follows the sequence of a real clinical setting, going from the first screening visit to the final stages of terminal patients. - Provides a quick-access resource for diagnosis and treatment of melanoma patients at all stages - Includes succinct guidelines, schematics, and figures for busy clinicians - Concludes with a section addressing special clinical situations, including melanoma in pregnancy, pediatric melanoma, familial melanoma and MPM, atypical Spitz tumor, occult primary melanoma, and the histopathologic gray zone |
| braf targeted therapy drugs: Comprehensive Medicinal Chemistry III Samuel Chackalamannil, David Rotella, Simon Edward Ward, Jörg Holenz, Ana Martinez, Carmen Gil, Helmut Buschmann, Norbert Handler, Andrea Wolkerstorfer, Andrew M. Davis, Colin Edge, Alan G. E. Wilson, Ian Collins, William Watkins, Louis J. Lombardo, Ved Srivastava, Adrian Hall, Santhosh Neelamkavil, Rob Jones, 2017 |
| braf targeted therapy drugs: Precision Medicine in Oncology Bulent Aydogan, James A. Radosevich, 2020-11-02 A FRESH EXAMINATION OF PRECISION MEDICINE'S INCREASINGLY PROMINENT ROLE IN THE FIELD OF ONCOLOGY Precision medicine takes into account each patient's specific characteristics and requirements to arrive at treatment plans that are optimized towards the best possible outcome. As the field of oncology continues to advance, this tailored approach is becoming more and more prevalent, channelling data on genomics, proteomics, metabolomics and other areas into new and innovative methods of practice. Precision Medicine in Oncology draws together the essential research driving the field forward, providing oncology clinicians and trainees alike with an illuminating overview of the technology and thinking behind the breakthroughs currently being made. Topics covered include: Biologically-guided radiation therapy Informatics for precision medicine Molecular imaging Biomarkers for treatment assessment Big data Nanoplatforms Casting a spotlight on this emerging knowledge base and its impact upon the management of tumors, Precision Medicine in Oncology opens up new possibilities and ways of working not only for oncologists, but also for molecular biologists, radiologists, medical geneticists, and others. |
| braf targeted therapy drugs: Medicinal Chemistry of Anticancer Drugs Carmen Avendaño, J. Carlos Menéndez, 2015-06-11 Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the surface or inside cancer cells, and resistance to antitumor drugs continues to be investigated. While these therapies are in their infancy, they hold promise of more effective therapies with fewer side effects. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book provides a sorely needed update from the point of view of medicinal chemistry and drug design. - Presents information in a clear and concise way using a large number of figures - Historical background provides insights on how the process of drug discovery in the anticancer field has evolved - Extensive references to primary literature |
| braf targeted therapy drugs: Pediatric Neuro-oncology Katrin Scheinemann, Eric Bouffet, 2015-03-26 “The editors...have done an outstanding job of presenting...complex information in a lucid manner – this book is a must-read for the global community of aspiring students and neuro-oncology practitioners.” Amar Gajjar, MD in the Foreword This is a succinct introduction to pediatric neuro-oncology. It summarizes the key advances in molecular biology that have helped transform this rapidly evolving field and provides up-to-date coverage of major and emerging treatment modalities as well as supportive care. Separate chapters present each kind of pediatric brain cancer and its diagnosis and treatment. As more children survive brain cancer, the importance of quality of life issues and helping survivors to cope with the neuropsychological impact and long-term effects of current therapies has come into sharper focus; these topics are also addressed in the book, as are palliative care and pediatric neuro-oncology in countries with limited resources. The book is aimed at trainees and practitioners who seek an up-to-date text in pediatric neuro-oncology that is both comprehensive and concise. |
| braf targeted therapy drugs: Adverse Events and Oncotargeted Kinase Inhibitors Giuseppe Tridente, 2017-05-08 Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases. A brief history of each drug's development and submission is provided, along with a more detailed analysis of the mechanism(s) of action involved in therapeutic activity or related to the insurgence of specific adverse events. Early chapters focus on general characteristics of TKIs, typology, and classification of adverse events, while the final chapters analyze TKIs as AE inducers and classes of AEs by system or organ involvement. This comprehensive resource compiles and critically reviews all of the relevant safety data for this class of drugs, with the goal of improving the understanding of pathogenesis and facilitating the prevention, monitoring, and management of these adverse events. - Offers a unique and comprehensive publication on the adverse events associated with a new and fast-growing class of medicines - Provides a systematic analysis of adverse events aimed at better prevention through understanding and offering insights for the development of safer drugs - Uses practical guidelines to establish a leading reference on this class of drugs for educators, researchers, drug developers, clinicians, safety professionals, and more |
| braf targeted therapy drugs: Medical and Health Genomics Dhavendra Kumar, Stylianos Antonarakis, 2016-06-04 Medical and Health Genomics provides concise and evidence-based technical and practical information on the applied and translational aspects of genome sciences and the technologies related to non-clinical medicine and public health. Coverage is based on evolving paradigms of genomic medicine—in particular, the relation to public and population health genomics now being rapidly incorporated in health management and administration, with further implications for clinical population and disease management. - Provides extensive coverage of the emergent field of health genomics and its huge relevance to healthcare management - Presents user-friendly language accompanied by explanatory diagrams, figures, and many references for further study - Covers the applied, but non-clinical, sciences across disease discovery, genetic analysis, genetic screening, and prevention and management - Details the impact of clinical genomics across a diverse array of public and community health issues, and within a variety of global healthcare systems |
| braf targeted therapy drugs: Cancer Immune Therapy Gernot Stuhler, Peter Walden, 2002-12-03 Cure or life with cancer? What can be achieved by cancer immune therapy? The past decade has seen substantial advancements in tumor immunology. Much of the new knowledge has been translated into new strategies for cancer treatment and into clinical trials. Some of these trials herald future breakthroughs, others have been disappointing and have prompted intensive search for alternatives.Major contributors to the field summarize the knowledge on the molecular and cellular mechanisms of tumorigenesis, critically review the instruments of the immune system that might be exploited for therapy, and discuss the clinical experiences with the different immune therapy concepts. Researchers in the fields of immunology, tumor biology and medicine will highly appreciate this up-to-date volume for evaluating future research activities. |
| braf targeted therapy drugs: Multi-Drug Resistance in Cancer Jun Zhou, 2012-08-09 Chemotherapy is one of the major treatment options for cancer patients; however, the efficacy of chemotherapeutic management of cancer is severely limited by multidrug resistance, in that cancer cells become simultaneously resistant to many structurally and mechanistically unrelated drugs. In the past three decades, a number of mechanisms by which cancer cells acquire multidrug resistance have been discovered. In addition, the development of agents or strategies to overcome resistance has been the subject of intense study. This book contains comprehensive and up-to-date reviews of multidrug resistance mechanisms, from over-expression of ATP-binding cassette drug transporters such as P-glycoprotein, multidrug resistance-associated proteins, and breast cancer resistance p- tein to the drug ratio-dependent antagonism and the paradigm of cancer stem cells. The book also includes strategies to overcome multidrug resistance, from the development of compounds that inhibit drug transporter function to the modulation of transporter expression. In addition, this book contains techniques for the detection and imaging of drug transporters, methods for the investigation of drug resistance in animal models, and strategies to evaluate the efficacy of resistance reversal agents. The book intends to provide a state-of-the-art collection of reviews and methods for both basic and clinician investigators who are interested in cancer multidrug resistance mechanisms and reversal strategies. Tianjin, China Jun Zhou v Contents Preface. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v Contributors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix 1 Multidrug Resistance in Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Bruce C. Baguley 2 Multidrug Resistance in Oncology and Beyond: From Imaging of Drug Efflux Pumps to Cellular Drug Targets . . . . . . . . . . . . . . . . . . . . . . . . . . |
| braf targeted therapy drugs: Clinical Trials in Oncology, Third Edition Stephanie Green, Jacqueline Benedetti, Angela Smith, John Crowley, 2012-05-09 The third edition of the bestselling Clinical Trials in Oncology provides a concise, nontechnical, and thoroughly up-to-date review of methods and issues related to cancer clinical trials. The authors emphasize the importance of proper study design, analysis, and data management and identify the pitfalls inherent in these processes. In addition, the book has been restructured to have separate chapters and expanded discussions on general clinical trials issues, and issues specific to Phases I, II, and III. New sections cover innovations in Phase I designs, randomized Phase II designs, and overcoming the challenges of array data. Although this book focuses on cancer trials, the same issues and concepts are important in any clinical setting. As always, the authors use clear, lucid prose and a multitude of real-world examples to convey the principles of successful trials without the need for a strong statistics or mathematics background. Armed with Clinical Trials in Oncology, Third Edition, clinicians and statisticians can avoid the many hazards that can jeopardize the success of a trial. |
| braf targeted therapy drugs: FDA's Drug Review Process and the Package Label Tom Brody, 2017-12-01 FDA's Drug Review Process and the Package Label provides guidance to pharmaceutical companies for writing FDA-submissions, such as the NDA, BLA, Clinical Study Reports, and Investigator's Brochures. The book provides guidance to medical writers for drafting FDA-submissions in a way more likely to persuade FDA reviewers to grant approval of the drug. In detail, the book reproduces data on efficacy and safety from one hundred different FDA-submissions (NDAs, BLAs). The book reproduces comments and complaints from FDA reviewers regarding data that are fragmentary, ambiguous, or that detract from the drug's approvability, and the book reveals how sponsors overcame FDA's concerns and how sponsors succeeded in persuading FDA to grant approval of the drug. The book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely text and data from NDAs and BLAs, as published on FDA's website. The source material for writing this book included about 80,000 pages from FDA's Medical Reviews, FDA's Clinical Pharmacology Reviews, and FDA's Pharmacology Reviews, from one hundred different NDAs or BLAs for one hundred different drugs. Each chapter focuses on a different section of the package label, e.g., the Dosage and Administration section or the Drug Interactions section, and demonstrates how the sponsor's data supported that section of the package label. - Reveals strategies for winning FDA approval and for drafting the package label - Examples are from one hundred FDA-submissions (NDAs, BLAs) for one hundred different drugs, e.g., for oncology, metabolic diseases, autoimmune diseases, and neurological diseases - This book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely, the data from NDAs and BLAs as published on FDA's website at the time FDA grants approval to the drug |
| braf targeted therapy drugs: Decision Modelling for Health Economic Evaluation Andrew Briggs, Mark Sculpher, Karl Claxton, 2006-08-17 In financially constrained health systems across the world, increasing emphasis is being placed on the ability to demonstrate that health care interventions are not only effective, but also cost-effective. This book deals with decision modelling techniques that can be used to estimate the value for money of various interventions including medical devices, surgical procedures, diagnostic technologies, and pharmaceuticals. Particular emphasis is placed on the importance of the appropriate representation of uncertainty in the evaluative process and the implication this uncertainty has for decision making and the need for future research. This highly practical guide takes the reader through the key principles and approaches of modelling techniques. It begins with the basics of constructing different forms of the model, the population of the model with input parameter estimates, analysis of the results, and progression to the holistic view of models as a valuable tool for informing future research exercises. Case studies and exercises are supported with online templates and solutions. This book will help analysts understand the contribution of decision-analytic modelling to the evaluation of health care programmes. ABOUT THE SERIES: Economic evaluation of health interventions is a growing specialist field, and this series of practical handbooks will tackle, in-depth, topics superficially addressed in more general health economics books. Each volume will include illustrative material, case histories and worked examples to encourage the reader to apply the methods discussed, with supporting material provided online. This series is aimed at health economists in academia, the pharmaceutical industry and the health sector, those on advanced health economics courses, and health researchers in associated fields. |
| braf targeted therapy drugs: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae? Kulmira Nurgali, R. Thomas Jagoe, Raquel Abalo, 2018-06-12 Advances in anti-cancer chemotherapy over recent years have led to improved efficacy in curing or controlling many cancers. Some chemotherapy-related side-effects are well recognized and include: nausea, vomiting, bone marrow suppression, peripheral neuropathy, cardiac and skeletal muscle dysfunction and renal impairment. However, it is becoming clearer that some chemotherapy-related adverse effects may persist even in long term cancer survivors. Problems such as cognitive, cardiovascular and gastrointestinal dysfunction, and neuropathy may lead to substantial long term morbidity. Despite improvements in treatments to counteract acute chemotherapy-induced adverse effects, they are often incompletely effective. Furthermore, counter-measures for some acute side-effects and many potential longer term sequelae of anti-cancer chemotherapy have not been developed. Thus, new insights into prevalence and mechanisms of cancer chemotherapy-related side effects are needed and new approaches to improving tolerance and reduce sequelae of cancer chemotherapy are urgently needed. The present Research Topic focuses on adverse effects and sequelae of chemotherapy and strategies to counteract them. |
| braf targeted therapy drugs: Fast Facts: Comprehensive Genomic Profiling Bernardo L. Rapoport , Giancarlo Troncone , Fernando Schmitt , Simon Nayler , 2020-10-20 Cancer is a multifaceted disease in which genetic changes induce uncontrolled tumor growth. Genomic characterization of cancer is now leading to better diagnostic, prognostic and predictive biomarkers, and effective individualized management. 'Fast Facts: Comprehensive Genomic Profiling' provides a crash course in the science, methods and application of genomic profiling. Assuming only the most basic knowledge – or memory – of cell biology, the authors provide an overview of DNA and RNA biology and next-generation sequencing. This sets in context the descriptions of prognostic and predictive biomarkers for different cancer types and genomic-based treatments. Finally, but importantly, some of the practicalities of gaining and interpreting genomic information are described. Whether you need a primer or a refresher, this short colorful book demystifies this complex subject. Contents: • Genetic mutations and biomarkers • Understanding next-generation sequencing • Elements of comprehensive genomic profiles • Role in precision oncology • Predictive and prognostic biomarkers • Overcoming barriers to genotype-directed therapy |
| braf targeted therapy drugs: Diagnosing and Treating Adult Cancers and Associated Impairments National Academies Of Sciences Engineeri, National Academies of Sciences Engineering and Medicine, Health And Medicine Division, Board On Health Care Services, Committee on Diagnosing and Treating Adult Cancers, 2021-11-10 Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer. |
| braf targeted therapy drugs: Cancer Immunology and Immunotherapy Mansoor M. Amiji, Lara Scheherazade Milane, 2021-08-18 Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. - Comprehensive treaty covering all aspects of immuno-oncology (IO) - Novel strategies for delivery of IO therapeutics and vaccines - Forecasting on the future of nanotechnology and drug delivery for IO |
| braf targeted therapy drugs: Dynamics Of Cancer: Mathematical Foundations Of Oncology Dominik Wodarz, Natalia Komarova, 2014-04-24 The book aims to provide an introduction to mathematical models that describe the dynamics of tumor growth and the evolution of tumor cells. It can be used as a textbook for advanced undergraduate or graduate courses, and also serves as a reference book for researchers. The book has a strong evolutionary component and reflects the viewpoint that cancer can be understood rationally through a combination of mathematical and biological tools. It can be used both by mathematicians and biologists. Mathematically, the book starts with relatively simple ordinary differential equation models, and subsequently explores more complex stochastic and spatial models. Biologically, the book starts with explorations of the basic dynamics of tumor growth, including competitive interactions among cells, and subsequently moves on to the evolutionary dynamics of cancer cells, including scenarios of cancer initiation, progression, and treatment. The book finishes with a discussion of advanced topics, which describe how some of the mathematical concepts can be used to gain insights into a variety of questions, such as epigenetics, telomeres, gene therapy, and social interactions of cancer cells. |
| braf targeted therapy drugs: Targeted Therapies in Cancer Marc Lacroix, 2016 Besides surgery, radiation therapy, endocrine therapy or chemotherapy, which were widely used in cancer patients for decades, the 21st century has seen the emergence of targeted therapy, resulting from the identification of molecular pathways in cells and their alterations in tumors. An increasing number of compounds targeting specific molecules or cancer cells have been developed and, for some of them, approved by the United States Food and Drug Administration (FDA) as well as other regulators in EU and Japan Additional new and more efficient types of compounds, are still in clinical trials, but are expected to gain future approval. More than eighty FDA-approved targeted therapies are described here, along with about eighty other promising compounds. These drugs are members of various therapy classes, including tyrosine kinase inhibitors; serine/threonine kinase inhibitors; dual specificity kinase inhibitors; lipid kinase inhibitors; poly ADP ribose polymerase inhibitors; monoclonal antibodies; microtubule targeting agents; histone deacetylase inhibitors; proteasome inhibitors; antimetabolites; immunomodulatory agents; DNA methyltransferase inhibitors; hedgehog pathway inhibitors; enzymes; protein translation inhibitors; vaccines, oncolytic viruses; chimeric antigen receptor T-cells (CAR-T); and so on. A series of companion diagnostics intended to be used as an indication for specific therapies, and approved to this aim are also mentioned. The book aims to present the broad landscape of compounds and companion diagnostics that are expected to pave the way towards a future of hope for cancer patients. |
| braf targeted therapy drugs: Molecular Modeling of Proteins Andreas Kukol, 2017-04-30 Molecular Modeling of Proteins, Second Edition provides a theoretical background of various methods available and enables non-specialists to apply methods to their problems by including updated chapters and new material not covered in the first edition. This detailed volume opens by featuring classical and advanced simulation methods as well as methods to set-up complex systems such as lipid membranes and membrane proteins and continues with chapters devoted to the simulation and analysis of conformational changes of proteins, computational methods for protein structure prediction, usage of experimental data in combination with computational techniques, as well as protein-ligand interactions, which are relevant in the drug design process. Written for the highly successful Methods in Molecular Biology series, chapters include thorough introductions, step-by-step instructions and notes on troubleshooting and avoiding common pitfalls. Update-to-date and authoritative, Molecular Modeling of Proteins, Second Edition aims to aid researchers in the physical, chemical and biosciences interested in utilizing this powerful technology. |
| braf targeted therapy drugs: Childhood Cancer and Functional Impacts Across the Care Continuum National Academies of Sciences Engineering and Medicine, Health and Medicine Division, Board on Health Care Services, Committee on Childhood Cancers and Disability, 2021-09-09 Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas. |
| braf targeted therapy drugs: BRAF Targets in Melanoma Ryan J. Sullivan, 2014-11-24 This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that this drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma. |
| braf targeted therapy drugs: Targeted Therapies in Breast Cancer Gw Sledge, George W. Sledge (Jr.), 2012-06 This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management. |
| braf targeted therapy drugs: Targeted Therapies for Solid Tumors Antonio Russo, Rafael Rosell, Christian Rolfo, 2015-03-11 This volume provides readers a comprehensive and state-of-the-art overview about the range of applications of targeted therapies for solid tumors. The sections of the book have been structured to review the oncogene addicted tumors, the pharmacology and clinical development of new molecularly targeted agents, the use of biomarkers as prognostic, predictive and surrogate endpoints, and the evaluation of tumor response and specific malignancies treated with targeted agents. The book also covers some of the newest developments in cancer therapy that are not adequately covered by any current available literature. Written by recognized experts in the field, Targeted Therapies for Solid Tumors: A Handbook for Moving Toward New Frontiers in Cancer Treatment provides a unique and valuable resource in the field of molecular oncology, both for those currently in training, and for those already in clinical or research practice. |
| braf targeted therapy drugs: Targeted Therapy in Translational Cancer Research Apostolia-Maria Tsimberidou, Razelle Kurzrock, Kenneth C. Anderson, 2015-10-08 Targeted Therapy in Translational Cancer Research for the Translational Oncology series provides a comprehensive overview of recent developments in our understanding of tumor biology, elucidates the roles of targets and pathways involved in carcinogenesis, and describes current state-of-the-art anticancer therapy, as well as the most promising areas of translational research and targeted therapy. Introduces cutting-edge ‘bench to bedside and back’ breakthroughs which have transformed the diagnosis, prognosis, and treatment of cancer Covers basic principles of targeted therapy, including immunotherapy and the roles of cancer stem cells, the microenvironment, angiogenesis, epigenetics, microRNAs, and functional imaging in precision medicine Summarises major advances in therapeutic management of hematologic malignancies and solid tumors using conventional therapy, targeted therapy, immunotherapy, or novel treatment modalities |
| braf targeted therapy drugs: Targeted Therapy of Colorectal Cancer Subtypes Peter Jordan, 2019-01-08 Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. Recent years have increased significantly our understanding of the genetic alterations that can underlie CRC, but also unraveled the molecular heterogeneity of the disease. Although a simple correlation between genetic pathways, histopathological features and clinical outcome cannot be established, the heterogeneity of CRC is also an opportunity for the development of targeted therapeutic approaches, able to treat an individual tumor with higher efficiency and less toxic side effects. One CRC subtype is characterized by high mutation rates (MSI-H), DNA methylation changes (CIMP-H), mutation in the BRAF oncogene and occurrence of serrated adenomas in the proximal colon. Other groups prevail in the distal colon and consist of either adenomatous polyps with chromosomal aberrations (CIN) and WNT pathway activation, or carry frequent KRAS mutation and metabolic deregulation, or have strong mesenchymal and infiltrative characteristics. Characterization of driver-mutation events in these CRC subgroups has led to the development of specific drugs targeting, for example, the MAPK pathway, but initial clinical trials have revealed unexpected response rates. The collection of chapters in this volume address the biology of specific CRC subtypes and how these may be targeted to improve precision therapy and clinical benefit for the patients. |
| braf targeted therapy drugs: Challenges and Opportunities of TKIs in the Treatment of NSCLC Patients With Uncommon Mutations Shi-Yong Sun, Chunxia Su, 2022-08-30 |
| braf targeted therapy drugs: Targeted Cancer Therapies, From Small Molecules to Antibodies Zhe-Sheng Chen, Jian-ye Zhang, Yunkai Zhang, Yan-yan Yan, 2020-07-22 |
| braf targeted therapy drugs: Mechanisms of Drug Resistance in Cancer Therapy Mario Mandalà, Emanuela Romano, 2019-01-10 A major objective of this book is to reveal unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive and prognostic biomarkers to enable patient stratification and tailor treatments. It offers to the readers an updated overview on the possible reasons of failure of new and promising therapeutic opportunities. |
BRAF — a tumour-agnostic drug target with lineage-specific …
In this Review, we describe the biochemical basis for oncogenic BRAF-induced activation of MAPK signalling and pan-cancer and lineage-specific mechanisms of intrinsic, adaptive and …
BRAF/MEK Inhibitor Therapy on managing adverse events …
These drugs are referred to as targeted therapies because they act on speci c protein targets in the MAPK pathway. BRAF/MEK inhibitor drugs are orally administered and have
Precision oncology for BRAF-mutant cancers with BRAF and …
In this review, we will focus on BRAF V600-targeted therapeutic options that are currently FDA approved (level 1) either as monotherapy or in combinations for treatment of BRAF-altered …
TARGETED THERAPY - go2.org
Research has found drugs called “targeted therapies” that attack cancer cells in new ways. Before we discuss targeted therapies, we will look at how cells work and how they can change into …
What, if Any, Role Is There for BRAF-Targeted Therapy in …
In summary, frontline BRAF-targeted therapy with combined BRAF and MEK inhibitor therapy in patients with advanced BRAF-mutant melanoma is associated with impressive 5-year …
BRAF-Targeted Therapy in the Treatment of BRAF-Mutant …
BRAF-Targeted Therapy in the Treatment of BRAF-Mutant High-Grade Gliomas in Adults Tanner M. Johanns, MD, PhD; George Ansstas, MD; and Sonika Dahiya, MD Use of small molecule …
U.S. FDA Approves Pfizer’s BRAFTOVI®
Dec 20, 2024 · BRAFTOVI® (encorafenib) is indicated, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a …
Specialty Guideline Management Braftovi - Caremark
Braftovi is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by …
BRAF/MEK Inhibitor Therapy Consensus statement from the …
Drugs that inhibit MEK include trametinib (Mekinist ®) and cobimetinib (Cotellic ) (Genentech, 2016; Novartis, 2017a). These agents inhibit hyperactive signaling in the MAPK pathway but …
Targeted Cancer Therapies - AAFP
Targeted cancer therapies involve chemotherapeutic agents that attack, directly or indirectly, a specific genetic biomarker found in a given cancer. Targeted oncology includes monoclonal...
Research Paper Identification of Potential BRAF Inhibitor …
Besides, we obtained four potential targeted drugs that could be used in combination with BRAFi to treat PTC, including MET inhibitor, ERBB3 inhibitor, anti-NaPi2b antibody-drug conjugate, …
Management of BRAF and MEK inhibitor - SAGE Journals
Since 2011, the specific BRAF targeted agents, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have been licensed for the treatment of patients with unresectable or …
Co-targeting SRC overcomes resistance to BRAF inhibitors …
This study explores SRC as a key mediator of resistance to BRAF inhibitors (BRAFi) in preclinical BRAFV600E CRC models, and its potential as a therapeutic target.
Realigned transsulfuration drives BRAF-V600E-targeted …
Mar 3, 2025 · BRAF V600E targeted therapy. Upregulated cystathionine-g-lyase (CSE)-induced H 2S/persulfide production is a crucial stress response, which protects proteins from oxidative …
TARGETED THERAPY - go2.org
Research has found drugs called “targeted therapies” that attack cancer cells in new ways. Before we discuss targeted therapies, we will look at how cells work and how they can change into …
Efficacy and toxicity of BRAF targeted therapy in elderly …
Conclusions: Treatment with BRAF & MEK inhibitors is challenging in older patients, with a high prevalence of toxicity leading to treatment modifications and discontinuation. Efficacy seems to …
What does it mean to have BRAF positive (BRAF+) Lung …
HOW DO DOCTORS TREAT BRAF+ LUNG CANCERS? A positive test for the BRAF biomarker means that you are eligible for targeted therapy. Targeted therapy drugs keep cancer from …
BRAF-targeted therapy for metastatic melanoma: rationale, …
development of BRAF targeted therapy. Several BRAF inhibitors have entered clinical trials, and have shown significant responses even in patients with late-stage melanoma. In this article, …
TARGETED THERAPY - go2.org
Research has found drugs called “targeted therapies” that attack cancer cells in new ways. Before we discuss targeted therapies, we will look at how cells work and how they can change into …
What is BRAF positive (BRAF+) Lung Cancer?
HOW DO DOCTORS TREAT BRAF+ LUNG CANCERS? A positive test for the BRAF biomarker means that you are eligible for targeted therapy. Targeted therapy drugs keep cancer from …
BRAF — a tumour-agnostic drug target with lineage-specific …
In this Review, we describe the biochemical basis for oncogenic BRAF-induced activation of MAPK signalling and pan-cancer and lineage-specific mechanisms of intrinsic, adaptive and …
BRAF/MEK Inhibitor Therapy on managing adverse events …
These drugs are referred to as targeted therapies because they act on speci c protein targets in the MAPK pathway. BRAF/MEK inhibitor drugs are orally administered and have
Precision oncology for BRAF-mutant cancers with BRAF and …
In this review, we will focus on BRAF V600-targeted therapeutic options that are currently FDA approved (level 1) either as monotherapy or in combinations for treatment of BRAF-altered …
TARGETED THERAPY - go2.org
Research has found drugs called “targeted therapies” that attack cancer cells in new ways. Before we discuss targeted therapies, we will look at how cells work and how they can change into …
What, if Any, Role Is There for BRAF-Targeted Therapy in …
In summary, frontline BRAF-targeted therapy with combined BRAF and MEK inhibitor therapy in patients with advanced BRAF-mutant melanoma is associated with impressive 5-year …
BRAF-Targeted Therapy in the Treatment of BRAF-Mutant …
BRAF-Targeted Therapy in the Treatment of BRAF-Mutant High-Grade Gliomas in Adults Tanner M. Johanns, MD, PhD; George Ansstas, MD; and Sonika Dahiya, MD Use of small molecule …
U.S. FDA Approves Pfizer’s BRAFTOVI®
Dec 20, 2024 · BRAFTOVI® (encorafenib) is indicated, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a …
Specialty Guideline Management Braftovi - Caremark
Braftovi is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by …
BRAF/MEK Inhibitor Therapy Consensus statement from the …
Drugs that inhibit MEK include trametinib (Mekinist ®) and cobimetinib (Cotellic ) (Genentech, 2016; Novartis, 2017a). These agents inhibit hyperactive signaling in the MAPK pathway but …
Targeted Cancer Therapies - AAFP
Targeted cancer therapies involve chemotherapeutic agents that attack, directly or indirectly, a specific genetic biomarker found in a given cancer. Targeted oncology includes monoclonal...
Research Paper Identification of Potential BRAF Inhibitor …
Besides, we obtained four potential targeted drugs that could be used in combination with BRAFi to treat PTC, including MET inhibitor, ERBB3 inhibitor, anti-NaPi2b antibody-drug conjugate, …
Management of BRAF and MEK inhibitor - SAGE Journals
Since 2011, the specific BRAF targeted agents, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have been licensed for the treatment of patients with unresectable or …
Co-targeting SRC overcomes resistance to BRAF inhibitors …
This study explores SRC as a key mediator of resistance to BRAF inhibitors (BRAFi) in preclinical BRAFV600E CRC models, and its potential as a therapeutic target.
Realigned transsulfuration drives BRAF-V600E-targeted …
Mar 3, 2025 · BRAF V600E targeted therapy. Upregulated cystathionine-g-lyase (CSE)-induced H 2S/persulfide production is a crucial stress response, which protects proteins from oxidative …
TARGETED THERAPY - go2.org
Research has found drugs called “targeted therapies” that attack cancer cells in new ways. Before we discuss targeted therapies, we will look at how cells work and how they can change into …
Efficacy and toxicity of BRAF targeted therapy in elderly …
Conclusions: Treatment with BRAF & MEK inhibitors is challenging in older patients, with a high prevalence of toxicity leading to treatment modifications and discontinuation. Efficacy seems to …
What does it mean to have BRAF positive (BRAF+) Lung …
HOW DO DOCTORS TREAT BRAF+ LUNG CANCERS? A positive test for the BRAF biomarker means that you are eligible for targeted therapy. Targeted therapy drugs keep cancer from …
BRAF-targeted therapy for metastatic melanoma: rationale, …
development of BRAF targeted therapy. Several BRAF inhibitors have entered clinical trials, and have shown significant responses even in patients with late-stage melanoma. In this article, …
TARGETED THERAPY - go2.org
Research has found drugs called “targeted therapies” that attack cancer cells in new ways. Before we discuss targeted therapies, we will look at how cells work and how they can change into …
What is BRAF positive (BRAF+) Lung Cancer?
HOW DO DOCTORS TREAT BRAF+ LUNG CANCERS? A positive test for the BRAF biomarker means that you are eligible for targeted therapy. Targeted therapy drugs keep cancer from …
